Medicines for Malaria Venture
Digital Annual Report 2024
Malaria adapts, so must we
In 2024, Medicines for Malaria Venture (MMV) marked 25 years of commitment to beating one of humanity’s oldest and deadliest foes. To accelerate progress, MMV launched a bold new strategy charting a course toward a malaria-free future. One rooted in innovation, equity and shared purpose. It reaffirms our mission to develop next-generation tools and ensure they reach those who need them most.
Our latest annual report offers an in-depth overview of MMV’s activities, achievements and financial statements for 2024:
Digital Annual Report 2022
Throughout 2022, MMV continued working with our partners to bring forward antimalarials to protect and cure the world’s most underserved populations, enhance control efforts and progress toward the eventual eradication of the disease globally. Our latest annual report offers an in-depth overview of MMV’s activities, achievements and financial statements for 2022. Read more.
Latest news and views
Explore the business plan to cure, prevent and eliminate malaria.
Upcoming events
MMV was formed as a product development partnership (PDP) 25 years ago in response to antimalarial drug resistance – the drugs were failing to treat the disease. Together with our partners, we’ve come a long way in developing and delivering new antimalarials and saving more lives, but the fight against malaria is still a race against resistance. Today, we continue innovating and developing new ways to stay one step ahead of the malaria parasite while progressing towards the global goal of zero malaria deaths.
Spotlight on equity
Gender equity: Antimalarials for pregnant women
Women and girls are uniquely affected by malaria's health, economic and societal impacts. Malaria means a heightened risk of morbidity and mortality for pregnant women and girls and their newborns. This, in turn, contributes to keeping women and girls away from school and work, exacerbating gender inequalities in education and in the workplace, and ultimately intensifying gendered power imbalances in society. Read more about antimalarial drugs for pregnant women and how MMV works to remedy this with the Malaria in Mothers and Babies (MiMBa) strategy.
Equitable partnerships: MMV's approach
MMV’s equitable partnerships strategy aims to promote local ownership of R&D processes, expand clinical trial capacity and strengthen local research infrastructure, thus delivering sustainable impact. MMV successfully supports locally led partnerships (where endemic countries lead the decision-making) and co-creation partnerships (where decision-making is shared with partners) every step of the way – from conducting drug trials and bolstering clinical trial capacity, through working with pharmaceutical manufacturers, to generating evidence to steer policy change. MMV has identified four pillars of work to strengthen equitable partnerships in the Global South:
1. People (sustainable capacity strengthening)
2. Discovery, chemistry and manufacturing
3. Clinical strategy
4. Communication and advocacy
